Winning ENTA Stock Forecast: Enanta Pharmaceuticals shows constant promising R&D results

June 18, 2018

Winning ENTA Stock Forecast: Enanta Pharmaceuticals shows constant promising R&D results

Enanta also has three clinical stage internally invented and wholly owned programs in areas of high unmet need namely NASH, PBC and RSV. And I would note, all three of these development programs now have fast track designation.

Jay Luly, President and CEO

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), incorporated on July 25, 1995, is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development

Pharma Stocks Forecast Winning Stock Forecast

Gilead Sciences Stock Analysis: Don’t Lump Gilead Sciences In With The Biotech Bubble

August 9, 2015

Gilead Sciences has not had the incredible breakout one would expect from its blowout earnings report.
The company’s management team has proven to be extremely capable and has a tendency to keep expectations low and soundly beating them.
The HCV franchise has given the company enough financial flexibility to fund future growth in case the current drug pipeline does not come through.
I Know First algorithm is bullish on Gilead Sciences over the next year, believing that it is certain to climb to new all-time highs

Based on the last price level, I Know First algorithm is bullish on this company going forward, believing it will surpass its all-time high and breakout to new levels from there.